Loading...
4166 logo

Orient Pharma Co., Ltd.TPEX:4166 Stock Report

Market Cap NT$5.3b
Share Price
NT$23.70
NT$25.77
8.0% undervalued intrinsic discount
1Y-25.9%
7D-7.4%
1D
Portfolio Value
View

Orient Pharma Co., Ltd.

TPEX:4166 Stock Report

Market Cap: NT$5.3b

Orient Pharma (4166) Stock Overview

Engages in the development of new drugs in Taiwan and internationally. More details

4166 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 4166 from our risk checks.

4166 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Orient Pharma Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Orient Pharma
Historical stock prices
Current Share PriceNT$23.70
52 Week HighNT$40.00
52 Week LowNT$22.30
Beta0.12
1 Month Change-9.02%
3 Month Change-10.23%
1 Year Change-25.94%
3 Year Change8.97%
5 Year Change55.41%
Change since IPO-37.11%

Recent News & Updates

Recent updates

Analysis Article Mar 22

Is Orient Pharma (GTSM:4166) A Risky Investment?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Jan 28

What Type Of Returns Would Orient Pharma's(GTSM:4166) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...
Analysis Article Dec 07

Does Orient Pharma (GTSM:4166) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

4166TW PharmaceuticalsTW Market
7D-7.4%3.7%2.6%
1Y-25.9%-5.2%94.7%

Return vs Industry: 4166 underperformed the TW Pharmaceuticals industry which returned -5.2% over the past year.

Return vs Market: 4166 underperformed the TW Market which returned 94.7% over the past year.

Price Volatility

Is 4166's price volatile compared to industry and market?
4166 volatility
4166 Average Weekly Movement6.0%
Pharmaceuticals Industry Average Movement5.3%
Market Average Movement6.2%
10% most volatile stocks in TW Market12.3%
10% least volatile stocks in TW Market2.5%

Stable Share Price: 4166 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 4166's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008n/aChun-Tong Huangwww.oppharma.com

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

Orient Pharma Co., Ltd. Fundamentals Summary

How do Orient Pharma's earnings and revenue compare to its market cap?
4166 fundamental statistics
Market capNT$5.29b
Earnings (TTM)NT$196.58m
Revenue (TTM)NT$1.41b
26.9x
P/E Ratio
3.7x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4166 income statement (TTM)
RevenueNT$1.41b
Cost of RevenueNT$604.20m
Gross ProfitNT$810.50m
Other ExpensesNT$613.92m
EarningsNT$196.58m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)0.88
Gross Margin57.29%
Net Profit Margin13.90%
Debt/Equity Ratio0%

How did 4166 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/25 17:44
End of Day Share Price 2026/05/25 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Orient Pharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.